Eiger BioPharmaceuticals (NASDAQ:EIGR) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Stock Performance

The stock has a market capitalization of $2.55 million, a price-to-earnings ratio of -0.03 and a beta of 1.83. The stock’s 50 day moving average is $5.04 and its 200 day moving average is $7.14. Eiger BioPharmaceuticals has a 1 year low of $1.10 and a 1 year high of $43.35.

Hedge Funds Weigh In On Eiger BioPharmaceuticals

Institutional investors have recently bought and sold shares of the business. Legal & General Group Plc increased its holdings in Eiger BioPharmaceuticals by 62.0% during the second quarter. Legal & General Group Plc now owns 4,327 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 1,656 shares during the period. Ergoteles LLC purchased a new position in Eiger BioPharmaceuticals during the second quarter valued at approximately $29,000. Marshall Wace LLP purchased a new position in Eiger BioPharmaceuticals during the fourth quarter valued at approximately $29,000. Annandale Capital LLC grew its holdings in Eiger BioPharmaceuticals by 22.3% in the fourth quarter. Annandale Capital LLC now owns 36,700 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 6,700 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in Eiger BioPharmaceuticals by 310.2% in the first quarter. Jane Street Group LLC now owns 56,661 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 42,848 shares during the last quarter. 62.46% of the stock is owned by hedge funds and other institutional investors.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.